Lucid Diagnostics INC. (LUCD) — SEC Filings

Overview

Lucid Diagnostics INC. (LUCD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 424B5 filed on Apr 23, 2026: Lucid Diagnostics Inc. filed a 424B5 prospectus supplement on April 23, 2026, related to its common stock. The filing details the terms of a proposed offering, including the number of shares and the price range, which are crucial for investors to understand the potential dilution and capital raised

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 4 bearish, 40 neutral, 1 mixed. The dominant filing sentiment for Lucid Diagnostics INC. is neutral.

Filing Type Overview

Lucid Diagnostics INC. (LUCD) has filed 1 424B5, 1 EFFECT, 27 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 3 SC 13D/A, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (45)

• Lucid Diagnostics Files Prospectus Supplement — 424B5 · Apr 23, 2026 Risk: medium
  Lucid Diagnostics Inc. filed a 424B5 prospectus supplement on April 23, 2026, related to its common stock. The filing details the terms of a proposed offering,
• EFFECT Filing — EFFECT · Mar 27, 2026
• Lucid Diagnostics Files 8-K on Financial Results & Reg FD — 8-K · Mar 26, 2026
  Lucid Diagnostics Inc. filed an 8-K on March 26, 2026, reporting on Items 2.02 (Results of Operations and Financial Condition) and 7.01 (Regulation FD Disclosur
• Lucid Diagnostics' Losses Mount Amidst Capital Injections — 10-Q · Nov 12, 2025 Risk: high
  Lucid Diagnostics Inc. reported a net loss attributable to common stockholders of $54.3 million for the nine months ended September 30, 2025, a significant incr
• Lucid Diagnostics Files 8-K on Officer/Director Changes — 8-K · Sep 25, 2025 Risk: medium
  Lucid Diagnostics Inc. filed an 8-K on September 25, 2025, reporting events as of September 22, 2025. The filing covers the departure of directors or certain of
• Lucid Diagnostics Files 8-K — 8-K · Sep 11, 2025 Risk: low
  Lucid Diagnostics Inc. filed an 8-K on September 11, 2025, reporting on other events and financial statements. The filing does not contain specific financial fi
• Lucid Diagnostics Files 8-K for Material Agreement — 8-K · Sep 10, 2025 Risk: medium
  Lucid Diagnostics Inc. filed an 8-K on September 10, 2025, reporting an entry into a material definitive agreement. The filing also includes Regulation FD discl
• Lucid Diagnostics Files 8-K on Financials — 8-K · Aug 13, 2025 Risk: low
  Lucid Diagnostics Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD d
• Lucid Diagnostics' Losses Widen Amid Rising Expenses, Going Concern Doubt — 10-Q · Aug 12, 2025 Risk: high
  Lucid Diagnostics Inc. reported a net loss attributable to common stockholders of $43.9 million for the six months ended June 30, 2025, a significant increase f
• Lucid Diagnostics Files 8-K — 8-K · Jun 18, 2025 Risk: low
  Lucid Diagnostics Inc. filed an 8-K on June 18, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing does not
• Lucid Diagnostics Files 8-K with Material Agreement — 8-K · May 30, 2025 Risk: medium
  On May 30, 2025, Lucid Diagnostics Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibit
• Lucid Diagnostics Files 8-K on Financials — 8-K · May 14, 2025 Risk: medium
  Lucid Diagnostics Inc. filed an 8-K on May 14, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disc
• Lucid Diagnostics Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: low
  Lucid Diagnostics Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including ch
• Lucid Diagnostics Files 2025 Proxy Statement — DEF 14A · Apr 30, 2025 Risk: low
  Lucid Diagnostics Inc. filed its definitive proxy statement (DEF 14A) on April 30, 2025, for the fiscal year ending December 31, 2024. The filing, which does no
• Lucid Diagnostics Changes Certifying Accountant — 8-K · Apr 25, 2025 Risk: low
  Lucid Diagnostics Inc. filed an 8-K on April 25, 2025, reporting a change in its certifying accountant as of April 23, 2025. The filing also includes financial
• Lucid Diagnostics Files 8-K — 8-K · Apr 11, 2025 Risk: low
  Lucid Diagnostics Inc. filed an 8-K on April 11, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other
• Lucid Diagnostics Files 8-K: Material Agreement & Financials — 8-K · Apr 10, 2025 Risk: medium
  Lucid Diagnostics Inc. filed an 8-K on April 10, 2025, reporting on events that occurred on April 9, 2025. The filing indicates the company entered into a mater
• Lucid Diagnostics Files 8-K on Financials — 8-K · Mar 25, 2025 Risk: low
  Lucid Diagnostics Inc. filed an 8-K on March 25, 2025, reporting on its results of operations and financial condition as of March 24, 2025. The filing also incl
• Lucid Diagnostics Files 2024 10-K — 10-K · Mar 24, 2025 Risk: medium
  Lucid Diagnostics Inc. filed its 10-K for the fiscal year ending December 31, 2024, on March 24, 2025. The company, based in New York, operates in the surgical
• Lucid Diagnostics Files 8-K — 8-K · Mar 5, 2025 Risk: low
  Lucid Diagnostics Inc. filed an 8-K on March 5, 2025, reporting on other events and financial statements. The company, incorporated in Delaware, has its princip
• Lucid Diagnostics Files 8-K — 8-K · Mar 4, 2025 Risk: low
  Lucid Diagnostics Inc. filed an 8-K on March 4, 2025, reporting other events and financial statements. The company, incorporated in Delaware, has its principal
• Lucid Diagnostics Files 8-K — 8-K · Feb 25, 2025 Risk: low
  Lucid Diagnostics Inc. filed an 8-K on February 25, 2025, reporting an event that occurred on February 24, 2025. The filing is categorized under 'Other Events'
• Lucid Diagnostics Files 8-K — 8-K · Dec 20, 2024 Risk: low
  Lucid Diagnostics Inc. filed an 8-K on December 20, 2024, reporting an event on December 19, 2024. The filing is categorized under 'Other Events' and 'Financial
• PAVmed Inc. Amends Lucid Diagnostics Stake Filing — SC 13D/A · Dec 12, 2024 Risk: medium
  PAVmed Inc. filed an amendment (No. 4) to its Schedule 13D on December 12, 2024, concerning its holdings in Lucid Diagnostics Inc. The filing indicates a change
• Lucid Diagnostics Reports Material Agreements and Equity Sales — 8-K · Nov 29, 2024 Risk: medium
  Lucid Diagnostics Inc. filed an 8-K on November 29, 2024, reporting on events as of November 22, 2024. The filing indicates the entry into and termination of ma
• Lucid Diagnostics Files 8-K: Agreements & Equity Sales — 8-K · Nov 18, 2024 Risk: medium
  Lucid Diagnostics Inc. entered into a material definitive agreement on November 12, 2024, which also resulted in the creation of a direct financial obligation.
• Lucid Diagnostics Files 8-K on Financials — 8-K · Nov 13, 2024 Risk: medium
  Lucid Diagnostics Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD
• Lucid Diagnostics Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Lucid Diagnostics Inc. filed its 10-Q for the period ending September 30, 2024. The filing covers financial results and operational updates for the third quarte
• Lucid Diagnostics Files Q2 2024 10-Q — 10-Q · Aug 12, 2024 Risk: medium
  Lucid Diagnostics Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial information and operational updates for the second quart
• Lucid Diagnostics Files 8-K on Corporate Actions — 8-K · Jul 24, 2024 Risk: low
  On July 23, 2024, Lucid Diagnostics Inc. filed an 8-K report detailing several corporate actions. The filing includes amendments to its articles of incorporatio
• SC 13G/A Filing — SC 13G/A · Jul 8, 2024
• Lucid Diagnostics Faces Delisting Notice — 8-K · Jun 21, 2024 Risk: high
  Lucid Diagnostics Inc. filed an 8-K on June 21, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is incorporate
• Lucid Diagnostics Files Definitive Proxy Statement — DEF 14A · Jun 6, 2024 Risk: low
  Lucid Diagnostics Inc. filed a Definitive Proxy Statement (DEF 14A) on June 6, 2024. This filing is related to the company's annual meeting and is not a fee-pay
• Lucid Diagnostics Files 8-K — 8-K · May 24, 2024 Risk: low
  Lucid Diagnostics Inc. filed an 8-K on May 24, 2024, reporting other events and financial statements/exhibits. The company, incorporated in Delaware with its pr
• Lucid Diagnostics Files 8-K on Financials — 8-K · May 14, 2024 Risk: medium
  Lucid Diagnostics Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition as of May 13, 2024. The filing also includes
• Lucid Diagnostics Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: medium
  Lucid Diagnostics Inc. (LUCD) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Lucid Diagnostics Inc. filed a 10-Q report for the period ending Mar
• Lucid Diagnostics Files 8-K with Key Corporate Updates — 8-K · May 7, 2024 Risk: medium
  On May 1, 2024, Lucid Diagnostics Inc. filed an 8-K report detailing several key events. These include unregistered sales of equity securities, material modific
• Lucid Diagnostics Files 8-K — 8-K · May 2, 2024 Risk: low
  Lucid Diagnostics Inc. filed an 8-K on May 2, 2024, reporting on financial statements and exhibits. The company, incorporated in Delaware, has its principal exe
• Lucid Diagnostics Inc. Announces Annual Meeting of Stockholders on June 20, 2024 — DEF 14A · Apr 29, 2024 Risk: low
  Lucid Diagnostics Inc. (LUCD) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Annual Meeting of Stockholders scheduled for June 20, 2024, at 1
• Lucid Diagnostics Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 25, 2024 Risk: medium
  Lucid Diagnostics Inc. (LUCD) filed a Annual Report (10-K) with the SEC on March 25, 2024. Lucid Diagnostics Inc. filed its 2023 Form 10-K on March 25, 2024. Th
• Lucid Diagnostics Files 8-K on Equity Sales & Bylaw Changes — 8-K · Mar 14, 2024 Risk: medium
  Lucid Diagnostics Inc. filed an 8-K on March 13, 2024, reporting on unregistered sales of equity securities and material modifications to security holder rights
• PAVmed Amends Lucid Diagnostics Stake — SC 13D/A · Feb 20, 2024 Risk: low
  PAVmed Inc. filed an SC 13D/A Amendment No. 3 on February 20, 2024, regarding its ownership of Common Stock, par value $0.001 per share, in Lucid Diagnostics In
• SC 13G Filing — SC 13G · Feb 14, 2024
• PAVmed Amends Lucid Diagnostics Stake, Ownership Update Filed — SC 13D/A · Feb 2, 2024
  PAVmed Inc. filed an amended Schedule 13D/A on February 2, 2024, indicating a change in its beneficial ownership of Lucid Diagnostics Inc. common stock, effecti
• Lucid Diagnostics Reports Unregistered Equity Sales — 8-K · Jan 30, 2024
  Lucid Diagnostics Inc. filed an 8-K on January 30, 2024, reporting unregistered sales of equity securities that occurred on January 26, 2024. This filing indica

Risk Profile

Risk Assessment: Of LUCD's 39 recent filings, 3 were flagged as high-risk, 18 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Lucid Diagnostics INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $3.2M
• Net Income: -$54.3M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $47.3M
• Operating Margin: N/A
• Total Assets: $53.2M
• Total Debt: $22.3M

Key Executives

• Lishan Aklog, M.D.

Industry Context

The diagnostic testing industry is highly competitive, with significant investment in R&D and a long path to commercialization for novel technologies. Companies like Lucid Diagnostics face pressure to demonstrate clinical utility and market adoption against established players and emerging innovations.

Top Tags

filing (8) · 8-K (8) · financials (7) · financial-condition (5) · corporate-governance (5) · material-agreement (4) · 8-k (4) · results-of-operations (4) · sec-filing (4) · 10-Q (4)

Key Numbers

• Document Size (form424b5.htm): 704843 — Size of the main prospectus filing document.
• Document Size (Complete submission text file): 710222 — Size of the full submission text file.
• Net Loss Attributable to Common Stockholders: $54.3M — Increased from $41.5M in 2024 for the nine months ended September 30.
• Revenue: $3.2M — Slight increase from $3.1M in 2024 for the nine months ended September 30, indicating slow growth.
• Net Cash Used in Operating Activities: $33.9M — Reflects ongoing operational burn for the nine months ended September 30, 2025.
• Cash Balance: $47.3M — Increased from $22.4M at December 31, 2024, primarily due to financing activities.
• Net Cash Provided by Financing Activities: $59.0M — Crucial for liquidity, including $43.2M from a Confidentially Marketed Public Offering.
• Senior Secured Convertible Notes: $22.3M — Classified as a current liability, posing a near-term financial obligation.
• Working Capital: $23.6M — Improved from a deficit, but still includes significant current debt.
• General and Administrative Expenses: $17.4M — Increased from $14.3M in 2024 for the nine months ended September 30.
• Research and Development Expenses: $3.9M — Decreased from $4.5M in 2024 for the nine months ended September 30.
• Common Shares Outstanding: 137,508,926 — As of September 30, 2025, indicating significant dilution from prior periods.
• Senior Secured Convertible Notes (Current Liability): $25.3M — Significant short-term debt obligation impacting working capital.
• Cash: $31.123M — Increased from $22.358M, primarily due to financing activities.
• Change in Fair Value - Senior Secured Convertible Note: $7.638M — Expense for 6 months ended June 30, 2025, a reversal from prior year income.

Related Companies

PAVM

Frequently Asked Questions